Gladstone in the News

The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.

Researchers develop blueprint for making a heart
October 5, 2012

Gladstone researchers say the discovery could have a profound impact on how we treat hearts and heart disease.

Battling back from a brain injury
October 3, 2012

Retired Senior Investigator Karl Weisgraber has had a long, difficult recovery from a fall off a ladder that caused a traumatic brain injury last October.

Mapping Genomic Blueprint
September 25, 2012

Scientists at the Gladstone Institutes have created the first "genomic blueprint" of the human heart, unveiling the exact order and timing of genetic events that must take place for an embryonic heart cell to become a beating, life-sustaining organ.

HIV patients aging prematurely
September 25, 2012

Gladstone investigators Eric Verdin, MD, and Shomyseh Sanjabi, PhD, are researching why patients living with HIV are aging prematurely.

New DNA Map May Help Cure Congenital Heart Defects
September 19, 2012

Reasearchers from Gladstone Institutes in California have created a blueprint map of how the heart developes in time.

Prevention drug still suggested to be taken daily, despite findings
September 19, 2012

Scientists led by a team at the Gladstone Institutes are getting closer to understanding how much antiretroviral medication people need to take to protect themselves from being infected with HIV.

DNA Blueprint Maps How A Heart Becomes A Heart
September 17, 2012

Using stem cell technology, next-generation DNA sequencing and computer tools, researchers at the Gladstone Institutes in California, and other academic centers, have mapped how a heart becomes a heart.

More Evidence That Truvada Can Help Prevent HIV
September 13, 2012

Truvada, the only medication approved by the U.S. Food and Drug Administration for HIV prevention, is effective in blocking the virus even if people do not adhere to their daily regimen perfectly, a new study indicates.

NIH-funded analysis estimates effective PrEP dosing
September 13, 2012

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.

Hepatitis C drugs offer hope for cure
September 11, 2012

Scientific breakthroughs, one piled on top of another at breakneck speed over the past few years, have put medical researchers on the cusp of curing almost everyone who suffers from hepatitis C, if not wiping out the disease entirely.